The drug major on Friday (8 May 2020) informed that the inspection of its three units at Pithampur in Madhya Pradesh by the UK health regulator has been completed.
The Medicines and Healthcare products Regulatory Agency (MHRA) of the UK conducted the inspection of the three units at Pithampur (Unit I, Unit II and Unit III) in January 2020, Lupin said in a statement.
Commenting on the positive outcome, Nilesh Gupta, managing director, Lupin said, We are committed to maintaining truly global quality standards at all our manufacturing facilities. The successful close out of the inspection at Pithampur, and release of the inspection report by UK MHRA further bolsters our confidence in our quality standards and manufacturing processes.
On a consolidated basis, Lupin reported a net loss of Rs 835 crore in Q3 December 2019 as against a net loss of Rs 151.75 crore in Q3 December 2018. Net sales declined 2.75% to Rs 3,716.09 crore in Q3 December 2019 over Q3 December 2018.
Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) in over 100 markets across the world.
Shares of the pharmaceutical company rose 2.65% to end at Rs 835.20 on Friday.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
